This is a working overview of deamidation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
1.0 L PC, 45 PS (33 kW; 44 hp) / 51 lb⋅ft (69 N⋅m) – export only 1.3 L TC (1977.01–1980) 60 PS (44 kW; 59 hp) / 72 PS (53 kW) in Japan 1.4 L UC (1978.03–1980) 83 PS (61 kW) in Japan In Australia the 1.3 had 45 kW (61 PS; 60 hp) at 5700 rpm while the bigger 1.4, introduced in July 1978, offered 48 kW (65 PS; 64 hp) at a somewhat lower engine speed of 5500 rpm. The 1.4 was accompanied by the new, better-equipped CS model which was only available with five-door bodywork. Van engines:
== Treatment == Currently this sub-type of muscular dystrophy has no cure and no definitive treatment exists. Treatment offers preventative tactics to delay muscle breakdown and increase life expectancy. Stretching and physical therapy can increase mobility. Treatment also includes correcting skeletal abnormalities through orthopedic surgery and other orthopedic techniques. Antiepileptic medication is administered to help prevent seizures. ACE inhibitors and beta blockers help treat heart conditions, and respiratory assistance is more than likely needed at some point for the affected individual.
=== Block === In most US cities, a city block is between 1⁄16 and 1⁄8 mi (100 and 200 m). In Manhattan, the measurement "block" usually refers to a north–south block, which is 1⁄20 mi (80 m). Sometimes people living in places (like Manhattan) with a regularly spaced street grid will speak of long blocks and short blocks. Within a typical large North American city, it is often only possible to travel along east–west and north–south streets, so travel distance between two points is often given in the number of blocks east–west plus the number north–south (known to mathematicians as the Manhattan distance).
=== Behavioral symptoms === Compulsive weighing Regular body checking Food restriction, both in terms of caloric content and type (for example, macronutrient groups) Food rituals, such as cutting food into tiny pieces and measuring it, refusing to eat around others, and hiding or discarding of food Purging, which may be achieved through self-induced vomiting, laxatives, diet pills, emetics, diuretics, or exercise Excessive exercise or compulsive movement, such as pacing Self harming or self-loathing Social withdrawal and solitude, resulting from the avoidance of friends, family, and events where food may be present Excessive water consumption to create a false impression of satiety Excessive caffeine consumption
== Tourism == One of Ningxia's main tourist spots is the internationally renowned Xixia Tombs site located 30 km (19 mi) west of Yinchuan. The remnants of nine Western Xia emperors' tombs and two hundred other tombs lie within a 50 km2 (19 sq mi) area. Other famous sites in Ningxia include the Helan Mountains, the mysterious 108 stupas, the twin pagodas of Baisikou and the desert research outpost at Shapotou. A less visited tourist spot in Ningxia is the Mount Sumeru Grottoes (须弥山), which is among the ten most famous grottoes in China.
Sources: en.wikipedia.org
PaTx1 is 83.3% identical to PATx2, differing only by two acidic residues(Chagot 2004)(Diochot 1999). Phrixotoxin-1 and -2 are similar to heteropodatoxin, which also has a blocking activity on Kv4.2 channels (Chagot 2004). Phrixotoxin-1, -2 and -3 contain an Inhibitor Cystine Knot (ICK) motif, and thus belong to the ICK peptide family(Chagot 2004)(Bosmans 2006).
PeptideAtlas is a proteomics data resource that gathers tandem mass spectrometry datasets from around the world, reprocesses them with the Trans-Proteomic Pipeline, and makes the combined result freely available to the community. Peptide Atlas is one of the founding members of the ProteomeXchange Consortium.
The Israeli Ground Forces (Hebrew: זְרוֹעַ הַיַּבָּשָׁה, romanized: z'róa hibshá, lit. 'The Land Arm') are the army of the Israel Defense Forces (IDF). The current commander of the ground forces is Major General Nadav Lotan. An order from Defense Minister David Ben-Gurion on 26 May 1948 officially set up the Israel Defense Forces as a conscript army formed out of the paramilitary group Haganah, incorporating the militant groups Irgun and Lehi. The Ground Forces have served in all the country's major military operations—including the 1948 Arab–Israeli War, 1956 Suez Crisis, 1967 Six-Day War, 1973 Yom Kippur War, 1976 Operation Entebbe, 1982 Lebanon War, 1987–1993 First Intifada, 2000–2005 Second Intifada, 2006 Lebanon War, and the Gaza War (2008–09). While originally the IDF operated on three fronts—against Lebanon and Syria in the north, Jordan and Iraq in the east, and Egypt in the south—after the 1979 Egyptian–Israeli Peace Treaty, it has concentrated in southern Lebanon and the Palestinian territories, including the First and the Second Intifada. The Ground Forces uses several technologies developed in Israel such as the Merkava main battle tank, Achzarit armoured personnel carrier, the Iron Dome missile defense system, Trophy active protection system for vehicles, and the Galil and Tavor assault rifles. The Uzi submachine gun was invented in Israel and used by the Ground Forces until December 2003, ending a service that began in 1954.
=== Uhlenhuth test === The Uhlenhuth test, or the antigen–antibody precipitin test for species, was invented by Paul Uhlenhuth in 1901 and could distinguish human blood from animal blood, based on the discovery that the blood of different species had one or more characteristic proteins. The test represented a major breakthrough and came to have tremendous importance in forensic science. The test was further refined for forensic use by the Swiss chemist Maurice Müller in the year 1960s.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.